Fresenius Kabi biosimilar candidate meets primary endpoints in the two pivotal clinical studies

Fresenius Kabi has reached a milestone on the road to approval for another biosimilar. MSB11455, a biosimilar candidate for Neulasta ® (pegfilgrastim), has met its primary endpoints in the two pivotal clinical studies. For more information please see the website of Fresenius Kabi.

The release as fetched from its publisher. fresenius.com ↗